# To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

> **NCT00050661** · PHASE1,PHASE2 · COMPLETED · sponsor: **Rockefeller University** · enrollment: 6 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Daclizumab
- **DEVICE:** NB-UVB

## Key facts

- **NCT ID:** NCT00050661
- **Lead sponsor:** Rockefeller University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-10
- **Primary completion:** 2004-04
- **Final completion:** 2008-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2009-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050661, "To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00050661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*